Effects of Intrathecal Midazolam (1mg) With Hyperbaric Bupivacaine 0.5% (15mg) for Spinal Anesthesia for C-section

Active, not recruitingOBSERVATIONAL
Enrollment

64

Participants

Timeline

Start Date

February 28, 2024

Primary Completion Date

July 1, 2024

Study Completion Date

March 1, 2025

Conditions
Cesarean Section Complications
Interventions
DIAGNOSTIC_TEST

group 1

A comparative analysis was conducted to assess sensory and motor block characteristics, postoperative analgesia duration, maternal hemodynamic stability, and neonatal outcomes. Results demonstrated that intrathecal midazolam significantly prolonged postoperative analgesia and reduced analgesic requirements while maintaining hemodynamic stability and maternal-neonatal safety. This combination provides a potential enhancement to spinal anesthesia techniques, improving maternal comfort and overall perioperative outcomes in obstetric patients.

Trial Locations (1)

Unknown

Nowshera, Nowshera

All Listed Sponsors
lead

Superior University

OTHER

NCT06748794 - Effects of Intrathecal Midazolam (1mg) With Hyperbaric Bupivacaine 0.5% (15mg) for Spinal Anesthesia for C-section | Biotech Hunter | Biotech Hunter